IP Library Granted Patent US 10,973,918
Granted Patent B2
US 10,973,918 · App. 16/591,025 · Granted Apr 13, 2021

Composition and methods for treating acute diarrhea and enteric infections in animals

Inventor: Thomas A. Schultz (Oviedo, FL)
Assignee: ANUBIS BIO CORPORATION
A61K39/42A23K20/147A23K50/40A61K35/20A61K35/57A61P1/12A61P31/04A61P31/20A61K2039/552
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,973,918
App. No.
16/591,025
Granted
Apr 13, 2021
Kind
B2
Abstract

The composition may be used therapeutically or prophylactically and is directed toward a cluster of diarrhea-causing pathogens which cause illness or death in animals, including dogs and cats. It is prepared from a powdered egg preparation and powdered protein matrix, such as bovine colostrum. The eggs are collected from hens which have been immunized with the relevant pathogens or toxins. When the matrix includes colostrum, the powdered colostrum is derived from non-hyperimmune cattle. The vaccination strategy includes the use of antibody cross-reactivity between toxins or pathogens which cause diarrhea. For some diseases, including canine parvo, the clinical improvement using this therapeutic exceeds the standard of care. Instead of a pharmaceutical product, this composition is an orally administered food product with the same safety profile as eggs and milk.

Claims (6)

1. A composition for treatment or prevention of diarrhea or enteric infection in an animal, the composition comprising: a. a mixture of IgY antibodies specific for a plurality of antigens obtained from a plurality of organisms, wherein the organisms are coronavirus, Escherichia coli, Clostridium perfringens, Campylobacter fetus, Campylobacter jejuni , and parvovirus; and b. a protective matrix comprising non-hyperimmune colostrum, wherein the protective matrix comprises at least 20 percent of the composition by weight.

2. The composition of claim 1 , wherein the mixture of IgY antibodies is obtained from one or more eggs laid by one or more birds, wherein each of the one or more birds have been vaccinated with plurality of antigens.

3. The composition of claim 1 , wherein at least one of the plurality of epitopes is common to more than one of the plurality of organisms.

4. The composition of claim 1 , wherein each of the plurality of organisms causes diarrhea in members of the Canidae or Felidae families.

5. The composition of claim 1 , wherein the colostrum is obtained from a non-hyperimmune ruminant.

6. The composition of claim 5 , wherein the non-hyperimmune ruminant is bovine.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2025
From: STEVENS LAW GROUP
To: MAMMAL LABS INC.
Reel/Frame 070655/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2024
From: SINGER, KEVIN
To: STEVENS LAW GROUP
Reel/Frame 067467/0978 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2023
From: ANUBIS BIO CORP.
To: SINGER, KEVIN
Reel/Frame 064682/0936 →
COURT ORDER Recorded Aug 16, 2023
From: ANUBIS BIO CORP
To: RECEIVERSHIP SPECIALISTS
Reel/Frame 064609/0405 →
COURT ORDER Recorded Aug 16, 2023
From: ANUBIS BIO CORP.
To: SINGER, KEVIN
Reel/Frame 064612/0583 →
LIEN Recorded May 22, 2023
From: ANUBIS BIO CORP.
To: STEVENS LAW GROUP
Reel/Frame 063720/0825 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2019
From: SCHULTZ, THOMAS A.
To: ANUBIS BIO CORPORATION
Reel/Frame 050604/0931 →
Continuity (2)
Provisional Application 62740769 · Oct 3, 2018
Related Publication 20200108144A1 · Apr 9, 2020